Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethanesulfonic Acid Amide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethanesulfonic Acid Amide SCHEMBL27416092 | 1.00 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL28039728 | 0.96 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL28038 | 0.95 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL1996587 | 0.91 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL3480490 | 0.91 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL27673482 | 0.91 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL27765064 | 0.91 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL9859651 | 0.91 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL3402460 | 0.91 | — | — | |
| Ethanesulfonic Acid Amide SCHEMBL8937205 | 0.84 | CA2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | claimed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | claimed |
| EP-1718629-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR THE TREATMENT OF ARRHYTMIA | Nissan Chemical Industries, Ltd. (JP) | 2006-11-08 | — | — | EP | claimed |
| WO-2005080368-A2 | BENZOPYRAN COMPOUND USEFUL FOR THE TREATMENT OF ARRHYTMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-01 | — | — | WO | claimed |
| EP-4680611-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-20250268873-A1 | COMBINATION OF DUAL ATM AND DNA-PK INHIBITORS AND IMMUNOTHERAPEUTIC AGENTS FOR USE IN CANCER THERAPY | XRAD THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024189597-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-19 | — | — | WO | disclosed |
| CN-113395993-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-02-20 | — | — | CN | disclosed |
| CN-117412964-A | Substituted heterocyclic compounds and their use | 首药控股(北京)股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-112739699-B | Pyridopyrimidine compounds as histamine H4 receptor inhibitors | 费斯制药股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116583502-A | Bicyclic-heterocyclic derivatives and their use as orexin-2 receptor agonists | 欧瑞夏治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-1377879-A | New alpha-amino acid sulfuryl compounds, its preparing method and medicinal composition containing them | SEWIL LAB (FR) | 2002-11-06 | — | — | CN | disclosed |
| CN-1348442-A | Novel sulfonamide compounds and uses thereof | MERCK & CO INC (US) | 2002-05-08 | — | — | CN | disclosed |
| EP-1007073-A4 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMA CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-1007073-A1 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-06-14 | — | — | EP | disclosed |
| CN-1225629-A | Novel pyrrole derivatives | HOFFMANN LA ROCHE (CH) | 1999-08-11 | — | — | CN | disclosed |
| WO-1997046250-A1 | METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997033579-A1 | MEDICAMENTS COMPRISING 5HT1-LIKE RECEPTOR AGONISTS WITH AN INCREASED ABSORPTION | GLAXO GROUP LIMITED (GB) | 1997-09-18 | — | — | WO | disclosed |
| EP-0106123-B1 | NOVEL N-NITROSO COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCESSES FOR THEIR PREPARATION | AB LEO (SE) | 1986-01-02 | — | — | EP | disclosed |